Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John T Hunt

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Molecular Cancer Therapeutics|January 29, 2009
Discovery of ixabepiloneJohn T Hunt
Cancer Immunology, Immunotherapy : CII|July 23, 2013
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor modelsMaria Jure-Kunkel, Gregg Masters, Emel Girit, et al.
Molecular Cancer Therapeutics|December 10, 2020
Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 InhibitorAaron Balog, Tai-An Lin, Derrick Maley, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2016
Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitorsJay A Markwalder, Steven P Seitz, Yuval Blat, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2004
Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleusMark E Salvati, Aaron Balog, Donna D Wei, et al.
Journal of Medicinal Chemistry|July 23, 2004
Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor templateJohn T Hunt, Toomas Mitt, Robert Borzilleri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signalingTai W Wong, Francis Y Lee, Chiang Yu, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2008
Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitorsZhen-Wei Cai, Donna Wei, Robert M Borzilleri, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2005
Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitorsRobert M Borzilleri, Zhen-Wei Cai, Christopher Ellis, et al.
Experimental Cell Research|August 25, 2015
Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transportRandy L Talbott, Robert M Borzilleri, Charu Chaudhry, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Molecular Cancer Therapeutics|January 29, 2009
Discovery of ixabepiloneJohn T Hunt
Cancer Immunology, Immunotherapy : CII|July 23, 2013
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor modelsMaria Jure-Kunkel, Gregg Masters, Emel Girit, et al.
Molecular Cancer Therapeutics|December 10, 2020
Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 InhibitorAaron Balog, Tai-An Lin, Derrick Maley, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2016
Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitorsJay A Markwalder, Steven P Seitz, Yuval Blat, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2004
Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleusMark E Salvati, Aaron Balog, Donna D Wei, et al.
Journal of Medicinal Chemistry|July 23, 2004
Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor templateJohn T Hunt, Toomas Mitt, Robert Borzilleri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signalingTai W Wong, Francis Y Lee, Chiang Yu, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2008
Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitorsZhen-Wei Cai, Donna Wei, Robert M Borzilleri, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2005
Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitorsRobert M Borzilleri, Zhen-Wei Cai, Christopher Ellis, et al.
Experimental Cell Research|August 25, 2015
Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transportRandy L Talbott, Robert M Borzilleri, Charu Chaudhry, et al.
Pageof 4